MEREO BIOPHARMA GROUP PLC Peo Actually Paid Comp Amt
MEREO BIOPHARMA GROUP PLC (MREO) reported Peo Actually Paid Comp Amt of -$1.96 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-09.
Financial Statements › Cash Flow › Other Cash Flow Items
ecd:PeoActuallyPaidCompAmt · last filed 2026-04-09
| Period end | Peo Actually Paid Comp Amt 12 month |
|---|---|
| 2025-12-31 | -$1.96M DEF 14A · filed 2026-04-09 |
| 2024-12-31 | $6.18M DEF 14A · filed 2026-04-09 |
| 2023-12-31 | $5.45M DEF 14A · filed 2026-04-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |